ABSI News and Press, Absci Corporation From 03/28/24

2024-03-28 23:02:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

VANCOUVER, Wash. and NEW YORK, March 28, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will be participating in the upcoming 23 rd Annual Needham Virtual Healthcare Conference. Absci management is...

2024-03-22 16:15:03 ET Scotiabank analyst issues SECTOR OUTPERFORM recommendation for ABSI on March 22, 2024 03:00PM ET. The previous analyst recommendation was Sector Outperform. ABSI was trading at $4.905 at issue of the analyst recommendation. The overall analyst cons...

2024-03-21 11:27:23 ET More on Absci Absci: Differentiated Antibody Discovery Play Absci prices $75M equity offering at $4.50 per share Read the full article on Seeking Alpha For further details see: Absci GAAP EPS of -$0.25 misses by $0.01, revenue of $0...

Initiated IND-enabling studies for ABS-101, a potential best-in-class anti-TL1A antibody Entered into collaboration with AstraZeneca for up to $247M in deal value, plus royalties Strengthened balance sheet raising approximately $86M in gross proceeds through underwritten common ...

2024-03-06 08:45:57 ET More on Mid-day gainers & stocks. Dada Nexus Rides Closer To JD.com's Orbit With Management Shakeup Infobird to effect 1-for-8 reverse stock split to regain compliance with Nasdaq rules NIO, Dada Nexus and Luckin Coffee lead strong recovery...

VANCOUVER, Wash., March 01, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI) (“Absci”), a data-first generative AI drug creation company, today announced the closing of its underwritten public offering of 19,205,000 shares of its common stock at a public offering price of $...

VANCOUVER, Wash., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI) (“Absci”), a data-first generative AI drug creation company, today announced the pricing of an underwritten public offering of 16,700,000 shares of its common stock at a public offering price of $4....

VANCOUVER, Wash., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI) (“Absci”), a data-first generative AI drug creation company, announced today that it has commenced an underwritten public offering of $75.0 million of shares of its common stock. Absci also intends ...

2024-02-22 14:41:34 ET More on Amgen, Eli Lilly, etc. Pfizer's Post-Pandemic Pivot Pfizer: Turnaround Is Gaining Momentum Eli Lilly: Yes, It Is Too Late To Join The Party Novo to face Wegovy competition in India as local versions loom: Reuters Weight-...